Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million

Reuters

Mar 20

Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million

Sellas published its annual report (Form 10-K) for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 26.86 million.
Research and development expense fell 16.09% to USD 16.02 million, driven mainly by lower external clinical trial costs for GPS following completion of REGAL enrollment and for SLS009 following completion of Phase 2a enrollment.
General and administrative expense was USD 12.25 million.
Non-operating income rose more than doubled to USD 1.41 million, reflecting interest income on cash and cash equivalents.
Cash and cash equivalents were USD 71.79 million as of Dec. 31, 2025, and management said this, together with USD 42.6 million in warrant-exercise proceeds received after year-end, is expected to fund planned operations for at least the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001390478-26-000003), on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620276628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620276628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620276628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620276628","market":"nz","top_or_hot":-1,"title":"Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sellas published its annual report (Form 10-K) for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 26.86 million.\n        </li>\n<li>\n          Research and development expense fell 16.09% to USD 16.02 million, driven mainly by lower external clinical trial costs for GPS following completion of REGAL enrollment and for SLS009 following completion of Phase 2a enrollment.\n        </li>\n<li>\n          General and administrative expense was USD 12.25 million.\n        </li>\n<li>\n          Non-operating income rose more than doubled to USD 1.41 million, reflecting interest income on cash and cash equivalents.\n        </li>\n<li>\n          Cash and cash equivalents were USD 71.79 million as of Dec. 31, 2025, and management said this, together with USD 42.6 million in warrant-exercise proceeds received after year-end, is expected to fund planned operations for at least the next 12 months.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001390478-26-000003), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sellas published its annual report (Form 10-K) for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 26.86 million.\n        </li>\n<li>\n          Research and development expense fell 16.09% to USD 16.02 million, driven mainly by lower external clinical trial costs for GPS following completion of REGAL enrollment and for SLS009 following completion of Phase 2a enrollment.\n        </li>\n<li>\n          General and administrative expense was USD 12.25 million.\n        </li>\n<li>\n          Non-operating income rose more than doubled to USD 1.41 million, reflecting interest income on cash and cash equivalents.\n        </li>\n<li>\n          Cash and cash equivalents were USD 71.79 million as of Dec. 31, 2025, and management said this, together with USD 42.6 million in warrant-exercise proceeds received after year-end, is expected to fund planned operations for at least the next 12 months.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001390478-26-000003), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9tJqH:1","article_id":"2620276628","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620276628","pubTimestamp":1773950516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sellas published its annual report  for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 26.86 million.Research and development expense fell 16.09% to USD 16.02 million, driven mainly by lower external clinical trial costs for GPS following completion of REGAL enrollment and for SLS009 following completion of Phase 2a enrollment.General and administrative expense was USD 12.25 million.Non-operating income rose more than doubled to USD 1.41 million, reflecting interest income on cash and cash equivalents.Cash and cash equivalents were USD 71.79 million as of Dec. 31, 2025, and management said this, together with USD 42.6 million in warrant-exercise proceeds received after year-end, is expected to fund planned operations for at least the next 12 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLS":"SELLAS Life Sciences Group Inc."},"translate_title":"Sellas Life Sciences 2025财年净亏损收窄13%至2686万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":0.9},"content_text":"Sellas Life Sciences FY 2025 net loss narrowed 13% to USD 26.86 million\n    \n\n\n          Sellas published its annual report (Form 10-K) for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 26.86 million.\n        \n\n          Research and development expense fell 16.09% to USD 16.02 million, driven mainly by lower external clinical trial costs for GPS following completion of REGAL enrollment and for SLS009 following completion of Phase 2a enrollment.\n        \n\n          General and administrative expense was USD 12.25 million.\n        \n\n          Non-operating income rose more than doubled to USD 1.41 million, reflecting interest income on cash and cash equivalents.\n        \n\n          Cash and cash equivalents were USD 71.79 million as of Dec. 31, 2025, and management said this, together with USD 42.6 million in warrant-exercise proceeds received after year-end, is expected to fund planned operations for at least the next 12 months.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001390478-26-000003), on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}